Moderna Stock Fundamentals
| MRNA Stock | USD 41.11 2.86 7.48% |
Moderna fundamentals help investors to digest information that contributes to Moderna's financial success or failures. It also enables traders to predict the movement of Moderna Stock. The fundamental analysis module provides a way to measure Moderna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moderna stock.
At present, Moderna's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 1.4 B, whereas Total Revenue is forecasted to decline to about 4.9 B. Moderna | Select Account or Indicator |
Moderna Company Return On Asset Analysis
Moderna's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Moderna Return On Asset | -0.0955 |
Most of Moderna's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moderna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Moderna Total Assets
Total Assets |
|
Based on the latest financial disclosure, Moderna has a Return On Asset of -0.0955. This is 98.91% lower than that of the Biotechnology sector and 99.6% lower than that of the Health Care industry. The return on asset for all United States stocks is 31.79% lower than that of the firm.
Moderna Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Moderna's current stock value. Our valuation model uses many indicators to compare Moderna value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Moderna competition to find correlations between indicators driving Moderna's intrinsic value. More Info.Moderna is regarded fourth in return on equity category among its peers. It also is regarded fourth in return on asset category among its peers . At present, Moderna's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moderna's earnings, one of the primary drivers of an investment's value.Moderna's Earnings Breakdown by Geography
Moderna Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moderna's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moderna could also be used in its relative valuation, which is a method of valuing Moderna by comparing valuation metrics of similar companies.Moderna is currently under evaluation in return on asset category among its peers.
Moderna Current Valuation Drivers
We derive many important indicators used in calculating different scores of Moderna from analyzing Moderna's financial statements. These drivers represent accounts that assess Moderna's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moderna's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 6.9B | 580.2M | 6.2B | 37.2B | 33.5B | 35.2B |
Moderna ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Moderna's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Moderna's managers, analysts, and investors.Environmental | Governance | Social |
Moderna Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0955 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 10.31 B | ||||
| Shares Outstanding | 384.82 M | ||||
| Shares Owned By Insiders | 9.52 % | ||||
| Shares Owned By Institutions | 71.60 % | ||||
| Number Of Shares Shorted | 34.38 M | ||||
| Price To Earning | 6.37 X | ||||
| Price To Book | 1.33 X | ||||
| Price To Sales | 3.11 X | ||||
| Revenue | 6.85 B | ||||
| Gross Profit | 10.55 B | ||||
| EBITDA | (3.28 B) | ||||
| Net Income | (4.71 B) | ||||
| Cash And Equivalents | 8.35 B | ||||
| Cash Per Share | 21.73 X | ||||
| Total Debt | 1.24 B | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 2.10 X | ||||
| Book Value Per Share | 30.98 X | ||||
| Cash Flow From Operations | (3.12 B) | ||||
| Short Ratio | 7.59 X | ||||
| Earnings Per Share | (5.81) X | ||||
| Target Price | 77.55 | ||||
| Number Of Employees | 5.6 K | ||||
| Beta | 1.69 | ||||
| Market Capitalization | 15.82 B | ||||
| Total Asset | 18.43 B | ||||
| Retained Earnings | 13.61 B | ||||
| Working Capital | 7.31 B | ||||
| Current Asset | 850 K | ||||
| Current Liabilities | 2.44 M | ||||
| Net Asset | 18.43 B |
About Moderna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 568 M | 539.6 M | |
| Total Revenue | 6.8 B | 4.9 B | |
| Cost Of Revenue | 4.7 B | 4.9 B | |
| Stock Based Compensation To Revenue | 0.04 | 0.04 | |
| Sales General And Administrative To Revenue | 0.20 | 0.19 | |
| Research And Ddevelopement To Revenue | 0.71 | 0.67 | |
| Capex To Revenue | 0.10 | 0.10 | |
| Revenue Per Share | 17.93 | 11.39 | |
| Ebit Per Revenue | (0.62) | (0.65) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Moderna Piotroski F Score and Moderna Altman Z Score analysis. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (5.81) | Revenue Per Share 13.275 | Quarterly Revenue Growth 0.017 | Return On Assets (0.1) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.